MediciNova, Inc. – Sublease (March 1st, 2013)
This Sublease, dated as of this 27th day of February, 2013, between Denali Advisors LLC, a Delaware limited liability company (Sublandlord) and MediciNova, Inc., a Delaware corporation (Subtenant).
MediciNova, Inc. – Confidential Consulting Agreement (September 8th, 2011)
This Consulting Agreement (the Agreement) is executed as of the date shown on the signature page (the Effective Date), by and between FLG Partners, LLC, a California limited liability company (FLG), and the entity identified on the signature page (Client).
MediciNova, Inc. – EXECUTIVE EMPLOYMENT AGREEMENT Michael Coffee (June 16th, 2010)
This EXECUTIVE EMPLOYMENT AGREEMENT (this Agreement) is made as of June 14, 2010 by and between MEDICINOVA, INC, a Delaware corporation (MediciNova), and Michael Coffee (Executive), with reference to the following facts:
Avigen, Inc. – Assignment Agreement (March 16th, 2006)
This ASSIGNMENT AGREEMENT is made and entered into on December 19, 2005 (the Effective Date) by and between Avigen, Inc., a Delaware corporation having its principal place of business at 1301 Harbor Bay Parkway, Alameda, California 94502 (Avigen), and Genzyme Corporation, a Massachusetts corporation having its principal place of business at 500 Kendall Street, Cambridge, Massachusetts 02142 (Genzyme) (hereinafter, each of Avigen and Genzyme a Party and, collectively, the Parties).
Avigen, Inc. – Avigen Licenses Unique Neuroactive Compound for Disabling Neuromuscular Conditions From Sanochemia Product Currently Marketed in Europe ; Avigen to Develop and Commercialize in US Avigen CEO to Host Conference Call Tomorrow, Tuesday, January 17 at 11:00 a.m. (EST) (January 17th, 2006)
Alameda, CA, January 16, 2006 Avigen, Inc. (AVGN: NASDAQ), a biopharmaceutical company developing innovative therapies for the treatment of neurological conditions, announced today that it has signed an agreement with SDI Diagnostics International LTD (SDI), a division of Sanochemia Pharmazeutika AG, an Austrian-based pharmaceutical company. Under the terms of the agreement, Avigen receives an exclusive North American license to develop and commercialize proprietary formulations of the neuroactive compound tolperisone (AV650), a small molecule for the treatment of disabling neuromuscular conditions.